Frontlight ResearchEarly access
CompletedPhase 2
Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A
Key facts
- Who runs it
- Guangdong Raynovent Biotech Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 72 people enrolled
- Started
- 30 Nov 2024
- Ended
- 31 Jul 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- ZSP1273 granules
- Record updated
- 17 November 2025
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Subjects and their guardians who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately
- Male or female subjects aged ≥ 2 to ≤17 years at the time of signing the informed consent form
- Subjects with a diagnosis of influenza virus infection confirmed by all of the following:; Positive rapid antigen test (RAT) for influenza with nasal or throat swabs; The time interval between the onset of symptoms and enrollment is 72 hours or less; Fever ≥ 38ºC (axillary temperature); and at least one following respiratory symptoms associated with influenza virus infection is present
Who cannot take part
- Subjects with any medical history in gastrointestinal that interferes with the absorption of drugs;
- Immunodeficiency,including malignant tumor,organ or marrow transplant,human immunodeficiency virus [HIV] infection,or patients receiving immunosuppressant therapy 3 months prior to enrollment;
- Have received any other investigational products within 3 months prior to dosing;
- Subjects with concurrent infections requiring antimicrobial therapy;
- Subjects with severe influenza virus infection;
- Positive urine pregnancy test;
- Subjects who are considered inappropriate for the study by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial is conducted in China. The aim of the trial is to investigate safety,pharmacokinetics and pharmacodynamics of ZSP1273 granules
The 2 groups in the trial
- ZSP1273(Arm a)Treatment being tested
* ≥2 ,\<6 year old,dose 1 QD;5day * ≥6 ,\<12 year old,dose 2 QD;5day * ≥12,≤17 year old,dose 3 QD;5day
Treatment: ZSP1273 granules
- ZSP1273(Arm b)Treatment being tested
* ≥2 ,\<6 year old,dose 4 QD;5day * ≥6 ,\<12 year old,dose 5 QD;5day * ≥12,≤17 year old,dose 6 QD;5day
Treatment: ZSP1273 granules
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Open-label Phase 2 Study of ZSP1273 in Otherwise Healthy Children 2-17 Years Old With Influenza A
- Publications
- Record updated
- 17 November 2025